insulin lispro

(redirected from Lispro)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

insulin lispro

(lĭs′prō′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by a reversal in the order of lysine and proline in the B chain, used in the treatment of type 1 and type 2 diabetes.

insulin lispro

a pancreatic hormone.
indications It is used to treat ketoacidosis types I and II and types 1 and 2 diabetes mellitus.
contraindications Known hypersensitivity to this drug or to protamine prohibits its use.
adverse effects Anaphylaxis is a life-threatening effect of this drug. Other adverse effects include blurred vision, dry mouth, flushing, rash, urticaria, warmth, lipohypertrophy, swelling, redness, and rebound hyperglycemia (the Somogyi effect). Lipodystrophy and hypoglycemia are common side effects.

insulin lispro

A synthetic insulin with a very rapid onset and short duration of action. Diabetic patients typically use it immediately before meals to prevent postprandial hyperglycemia. Its absorption is more rapid than regular insulin. It is made by reversing the amino acids lysine and proline in the beta chain of the insulin polypeptide (hence its name lispro).
See also: insulin

insulin lispro

Very rapidly-acting INSULIN. A brand name is Humalog.
References in periodicals archive ?
AWARD-4 AWARD-4 was a randomized, 52-week, open-label comparison of the effects of once-weekly dulaglutide and insulin glargine, both in combination with insulin lispro, in patients with type 2 diabetes poorly controlled on a conventional insulin regimen.
Intra-subject variability study - This Phase 1 trial started in 1Q09 and is testing regular insulin with PH20, lispro with PH20 and lispro alone.
Intra-subject variability - This Phase 1 trial started in 1Q09 and will test regular insulin + PH20, lispro + PH20 and lispro alone.
Lispro 25/75 ile bifazik insan insulinin karsilastirildigi calismalarin bazilarinda hipoglisemi riski dusuk bulunurken bazen de anlamli bir fark tespit edilememistir (18-21).
The two rapidly acting insulin analogues resembled human insulin on all parameters, except for a slightly elevated IGF-1 receptor affinity for lispro (Diabetes 2000:49:999-1005).
Humalog Mix[R] 25 (75 percent insulin lispro protamine suspension and 25 percent insulin lispro injection) is a mixture of insulin lispro solution (Humalog[R]), that acts rapidly with insulin lispro protamine suspension, an intermediate acting, blood glucose towering agent.
Humalog (insulin lispro injection [rDNA origin]) is for use in patients with
The researchers have revealed that no difference was found between the short-acting insulin analogues, lispro and aspart, and human insulin.
In 2001 she switched from the insulin pump to glargine and lispro, with no change in Hb[A.
We obtained 3 kinds of recombinant insulin analogs, lispro (Humalog[R]; Eli Lilly and Company), aspart (NovoRapid[R] 300 F1exPen[R]; Novo Nordisk Pharmaceuticals), and glargine (Lantus[R]; Aventis Pharmaceuticals) and investigated whether they were detectable by these assays.
The pharmacokinetic properties of the new insulin analogs (eg, insulin lispro, insulin aspart, insulin glargine) offer significant advantages, such as improved control of nocturnal hypoglycemia with basal insulin glargine, and improved postprandial glucose control, with insulin lispro or insulin aspart.